T1	Participants 250 430	short-term treatment effects of atomoxetine on autism spectrum disorder (ASD) symptoms in children and adolescents with both ASD and attention-deficit/hyperactivity disorder (ADHD)
T2	Participants 451 499	97 patients 6-17 years of age, with ASD and ADHD
